# 12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease

> **NCT07034222** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Ruijin Hospital** · enrollment: 80 (estimated)

## Conditions studied

- Alzheimer's Disease(AD)

## Interventions

- **DRUG:** Administer Leqemi 10 mg/kg, every two weeks.

## Key facts

- **NCT ID:** NCT07034222
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-01
- **Primary completion:** 2026-01-01
- **Final completion:** 2026-01-01
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07034222

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07034222, "12-Month Real-World Safety & Efficacy of Lecanemab in Early Alzheimer's Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT07034222. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*